突发利空，美医药股大跌

Group 1 - The U.S. stock market experienced a decline on August 25, with the Dow Jones falling by 0.77%, the S&P 500 by 0.43%, and the Nasdaq by 0.22% [1] - Chinese concept stocks showed mixed performance, with the Nasdaq Golden Dragon China Index up by 0.11%, while companies like Douyu and Sohu rose over 3% [1] - President Trump announced plans to significantly reduce drug prices, aiming to cut them to 1/1400 to 1/1500 of current levels, which led to a broad decline in pharmaceutical stocks [1][3] Group 2 - Intel's stock fell by 1.01% after the company warned that the U.S. government's 10% stake could pose risks to its international sales and future subsidy eligibility [2] - The U.S. government is set to become Intel's largest shareholder by purchasing 9.9% of its stock at a price lower than the market value, which may dilute existing shareholders' equity [2] - In the last fiscal year, 76% of Intel's revenue came from international markets, highlighting the potential impact of government ownership on its global business [2] Group 3 - Major pharmaceutical companies like DexCom, Moderna, Pfizer, and Merck saw significant stock declines following Trump's announcement on drug price reductions [3] - DexCom's stock dropped over 7.6%, while Moderna fell by 6.53%, Pfizer by 2.86%, and Merck by 2.36% in response to the news [3]